Results 241 to 250 of about 21,199,011 (380)

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Only the strong survive: therapeutic selective pressure drives medulloblastoma leptomeningeal metastasis

open access: yesMolecular Oncology, EarlyView.
Radiation therapy induces cancer cell death and immune cell infiltration, mainly monocytes, macrophages, and dendritic cells. Elevated serum cytokine levels and disruption of the blood–brain barrier promote leptomeningeal dissemination. Cotreatment with dexamethasone reduces cytokine levels, preserves barrier integrity, and limits metastatic spread ...
Francis Y. He, Adrienne Boire
wiley   +1 more source

Home - About - Disclaimer - Privacy